发明名称 Heterocyclic compounds and their uses
摘要 Substituted bicyclic heteroaryls having the following formula; where the variables are as defined herein, and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110□ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
申请公布号 US8901135(B2) 申请公布日期 2014.12.02
申请号 US201213468234 申请日期 2012.05.10
申请人 Amgen Inc. 发明人 Chen Yi;Cushing Timothy D.;Duquette Jason A.;Gonzalez Lopez De Turiso Felix;Hao Xiaolin;He Xiao;Lucas Brian;McGee Lawrence R.;Reichelt Andreas;Rzasa Robert M.;Seganish Jennifer;Shin Youngsook;Zhang Dawei
分类号 C07D487/04;C07D473/34;C07D473/30 主分类号 C07D487/04
代理机构 代理人 Bulock Joseph W.
主权项 1. A compound having the structure:or any pharmaceutically-acceptable salt thereof, wherein: X1 is C(R9) or N; Y is N(R11), O or S; n is 0, 1, 2 or 3; R1 is a direct bonded or —O-linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R2 substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl; R2 is selected from halo, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —OC(═O)NRaRa, —OC(═O)N(Ra)S(═O)2Ra, —OC2-6alkylNRaRa, —OC2-6alkylORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O)Ra, —N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O) Ra, —N(Ra)C(═O)ORa, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Ra, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkylNRaRa and —NRaC2-6alkylORa; or R2 is selected from C1-6alkyl, phenyl, benzyl, heteroaryl, heterocycle, —(C1-3alkyl)heteroaryl, —(C1-3,alkyl)heterocycle, —O(C1-3alkyl)heteroaryl, —O(C1-3alkyl)heterocycle, —NRa(C1-3alkyl)heteroaryl, —NRa(C1-3alkyl)heterocycle, —(C1-3alkyl)phenyl, —O(C1-3alkyl)phenyl and —NRa(C1-3alkyl)phenyl all of which are substituted by 0, 1, 2 or 3 substituents selected from C1-4haloalkyl, OC1-4alkyl, Br, Cl, F, I and C1-4alkyl; R3 is selected from H, halo, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —OC(═)NRaRa, —OC(═O)N(Ra)S(═O)2Ra, —OC2-6alkylNRaRa, —OC2-6alkylORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O)Ra, —N(Ra)C(═O)ORa, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Ra, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkylNRaRa, —NRaC2-6alkylORa, C1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein the C1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1, 2 or 3 substituents selected from C1-6haloalkyl, OC1-6alkyl, Br, Cl, F, I and C1-6alkyl; R4 is, independently, in each instance, halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl or C1-4haloalkyl; R5 is, independently, in each instance, H, halo, C1-6alkyl, C1-4haloalkyl, or C1-6alkyl substituted by 1, 2 or 3 substituents selected from halo, cyano, OH, OC1-4alkyl, C1-3haloalkyl, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl; or both R5 groups together with the carbon atom to which they are attached form a C3-6cycloalkyl substituted by 0, 1, 2 or 3 substituents selected from halo, cyano, OH, OC1-4alkyl, C1-4alkyl, C1-3haloalkyl, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl; R6 is selected from H, halo, C1-6alkyl, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, R7 is selected from H, halo, C1-6alkyl, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa; R8 is selected from H, C1-6haloalkyl, Br, Cl, F, I, ORa, NRaRa, C1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein the C1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1, 2 or 3 substituents selected from C1-6haloalkyl, OC1-6alkyl, Br, Cl, F, I and C1-6alkyl; R9 is selected from H, halo, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —OC(═O)NRaRa, —OC(═O)N(Ra)S(═O)2Ra, —OC2-6alkylNRaRa, —OC2-6alkylORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O)Ra, —N(Ra)C(═O)ORa, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Ra, —N(Ra)S(═O)2NRaRa, —NRaRa, —NRaC2-6alkylORa, C1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle, wherein the C1-6alkyl, phenyl, benzyl, heteroaryl and heterocycle are additionally substituted by 0, 1, 2 or 3 substituents selected from halo, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —OC(═O)NRaRa, —OC(═O)N(Ra)S(═O)2Ra, —OC2-6alkylNRaRa, —OC2-6alkylORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O)Ra, —N(Ra)C(═O)ORa, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Ra, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkylNRaRa, —NRaC2-6alkylORa; or R9 is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O, and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0, 1, 2, 3 or 4 substituents selected from halo, C1-4haloalkyl, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —OC(═O)NRaRa, —OC(═O)N(Ra)S(═O)2Ra, —OC2-6alkylNRaRa, —OC2-6alkylORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O)Ra, —N(Ra)C(═O)ORa, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Ra, —N(Ra)S(═O)2NRaRa, NRaC2-6alkylNRaRa and —NRaC2-6alkylORa; R10 is H, C1-3alkyl, C1-3haloalkyl, cyano, nitro, CO2Ra, C(═O)NRaRa, —C(═NRa)NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, S(═O)Ra, S(═O)2Ra or S(═O)2NRaRa; R11 is H or C1-4alkyl; Ra is independently, at each instance, H or Rb; and Rb is independently, at each instance, phenyl, benzyl or C1-6alkyl, the phenyl, benzyl and C1-6alkyl being substituted by 0, 1, 2 or 3 substituents selected from halo, C1-4, C1-3haloalkyl, —OC1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)C1-4alkyl.
地址 Thousand Oaks CA US